Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E19.99 EPS (ttm)2.67 Insider Own0.16% Shs Outstand1.64B Perf Week2.71%
Market Cap87.50B Forward P/E13.19 EPS next Y4.05 Insider Trans0.00% Shs Float1.63B Perf Month0.09%
Income4.38B PEG1.81 EPS next Q0.84 Inst Own74.80% Short Float0.73% Perf Quarter-11.42%
Sales22.04B P/S3.97 EPS this Y-10.90% Inst Trans0.60% Short Ratio1.40 Perf Half Y-0.04%
Book/sh8.36 P/B6.39 EPS next Y4.81% ROA4.30% Target Price60.18 Perf Year-15.20%
Cash/sh4.17 P/C12.81 EPS next 5Y11.03% ROE11.30% 52W Range46.94 - 70.05 Perf YTD-12.79%
Dividend1.60 P/FCF78.55 EPS past 5Y15.30% ROI20.20% 52W High-23.71% Beta1.09
Dividend %2.99% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin70.80% 52W Low13.85% ATR1.42
Employees23700 Current Ratio1.50 Sales Q/Q8.30% Oper. Margin24.40% RSI (14)50.42 Volatility2.73% 2.34%
OptionableYes Debt/Eq0.54 EPS Q/Q128.60% Profit Margin6.50% Rel Volume0.87 Prev Close52.43
ShortableYes LT Debt/Eq0.42 EarningsJan 24 BMO Payout180.60% Avg Volume8.54M Price53.44
Recom2.50 SMA201.18% SMA50-1.80% SMA200-6.45% Volume7,447,179 Change1.93%
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Dec-13-18 07:06AM  Upgraded Broker Ratings Make These 5 Stocks Worth a Look Now Zacks
Dec-12-18 08:56AM  Roche to Create Companion Diagnostic Test for Merck's Keytruda Zacks
08:52AM  Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan Zacks
Dec-11-18 10:44AM  5 Companies That Raised Dividends as Bond Yields Increase
09:51AM  Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800 Zacks
Dec-10-18 12:17PM  Roche's Tecentriq Gets FDA Approval for First-Line NSCLC Zacks
07:00AM  Today's Research Reports on Trending Tickers: Johnson & Johnson and Bristol-Myers Squibb ACCESSWIRE
02:00AM  Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers Business Wire
Dec-08-18 08:09PM  Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds? Insider Monkey
05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
Dec-07-18 05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -0.32%: What You Should Know Zacks
04:42PM  CEO of Chapel Hill firm talks 2 new partnerships with big pharma American City Business Journals
03:14PM  Mallinckrodt (MNK) to Separate Generics & Branded Businesses Zacks
08:04AM  The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga
Dec-06-18 04:15PM  Bristol-Myers Squibb Announces Dividend Increase Business Wire
10:29AM  Bristol-Myers Stock Is Rising on an Analyst Upgrade
Dec-05-18 05:33PM  This stable value stock is built to weather market storms MarketWatch
08:45AM  Roche's Tecentriq Combination Gets Priority Review by FDA Zacks
06:59AM  Bristol-Myers Squibb to Announce Results for Fourth Quarter 2018 on January 24 Business Wire
Dec-04-18 04:58PM  J&J Strikes Deal with argenx to Co-Develop Cancer Antibody Zacks
02:39PM  Roche Announces Positive Data on Venclexta/Venclyxto at ASH Zacks
08:57AM  The Zacks Analyst Blog Highlights: Shoe Carnival, On Deck, DXP, Arch Coal and Bristol-Myers Zacks
Dec-03-18 05:00PM  Bristol-Myers Squibb to Transfer $3.8 billion in U.S. Pension Liabilities Business Wire
09:47AM  Shire's Takhzyro Gets European Nod for Hereditary Angioedema Zacks
07:58AM  5 Best Stocks to Own This December Zacks
Nov-30-18 03:19PM  Novartis' Gilenya Approved in EU for Expanded Population Zacks
09:15AM  Lilly (LLY) Hits Fresh High: Is There Still Room to Run? Zacks
09:06AM  Bayer (BAYRY) to Restructure Business & Reduce Headcount Zacks
Nov-29-18 04:30PM  Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting Business Wire
08:33AM  Catalyst's Firdapse Receives FDA Approval for Rare Disease Zacks
06:59AM  Bristol-Myers Squibb to Take Part in Citi 2018 Global Healthcare Conference Business Wire
Nov-28-18 05:45PM  Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
05:09PM  Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity Zacks
09:30AM  Company News For Nov 28, 2018 Zacks
06:50AM  Todays Research Reports on Stocks to Watch: IntelliPharmaCeutics International and Bristol-Myers Squibb ACCESSWIRE
Nov-27-18 04:56PM  What Happened in the Stock Market Today Motley Fool
04:54PM  Spirit Airlines jumps while United Technologies tumbles Associated Press
04:40PM  This Pharma Giant Is Still Consolidating Despite Lung Cancer Flop Investor's Business Daily
04:39PM  US STOCKS-Wall St reverses losses after White House adviser's trade remarks Reuters
03:41PM  Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate Zacks
03:33PM  Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial Zacks
11:10AM  Bristol-Myers Drops After Lung-Cancer Drug Study Fails
09:40AM  Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan Zacks
09:25AM  [$$] Stocks to Watch: Apple, GM, United Technologies The Wall Street Journal
09:19AM  Dont Sell Bristol-Myers Squibb Company (NYSE:BMY) Before You Read This Simply Wall St.
08:54AM  Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors Zacks
07:36AM  Stocks making the biggest move premarket: UTX, AAPL, HIBB, NVS, TSLA & more CNBC
07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga
Nov-26-18 05:37PM  AMAG's Label Expansion of Lead Products Raises Share Price Zacks
05:13PM  After-hours buzz: AAPL, GM & more CNBC
05:04PM  Bristol-Myers Squibb says cancer drug combination fails late-stage trial Reuters
04:47PM  Bristol-Myers Squibb shares decline on failed lung-cancer drug study MarketWatch
04:30PM  Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemotherapy Business Wire
09:33AM  Glaxo Inks Marketing Deal for Anaemia Candidate in Japan Zacks
06:59AM  Bristol-Myers Squibb Awards Golden Tickets for LabCentral to ReviveMed, Strand Therapeutics Business Wire
Nov-25-18 11:30AM  Better Buy: Pfizer vs. Bristol-Myers Squibb Motley Fool
Nov-23-18 02:05PM  Bayer Hurts from Generic Competition & Pipeline Setbacks Zacks
Nov-22-18 09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
09:16AM  Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days Zacks
Nov-21-18 12:32PM  How to invest in the wake of the stock market rout Yahoo Finance
10:47AM  Bright spots emerge despite stock volatility Yahoo Finance Video
10:04AM  Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility Zacks
09:36AM  Shire-Takeda Deal Gets Phase I Conditional European Approval Zacks
09:30AM  Is Bristol-Myers (BMY) a Great Stock for Value Investors? Zacks
09:02AM  Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up Zacks
Nov-20-18 05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
08:25AM  Investor Expectations to Drive Momentum within Bristol-Myers Squibb, Leaf Group, SendGrid, Exantas Capital, Under Armour, and Medley Management Discovering Underlying Factors of Influence GlobeNewswire
08:12AM  Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails Zacks
06:59AM  Bristol-Myers Squibb to Take Part in Evercore ISI HealthCONx Conference Business Wire
Nov-19-18 09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
Nov-18-18 09:17AM  [$$] Why the Corporate Earnings Boom Has Failed to Lift Investors' Spirits The Wall Street Journal
Nov-16-18 02:52PM  Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC Zacks
10:29AM  Is Paypal Holdings Inc (PYPL) A Good Investment Right Now? Insider Monkey
08:35AM  Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks
08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-15-18 04:30PM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Business Wire
04:09PM  Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug Zacks
12:19PM  Bristol-Myers Squibb lays off employees in Tampa office American City Business Journals
09:16AM  Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx Zacks
Nov-14-18 05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
09:07AM  Can These 2 Battered Biotech Stocks Recover? Motley Fool
08:02AM  Shire's Filing Accepted by FDA for Gattex's Label Expansion Zacks
Nov-13-18 01:17PM  Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-12-18 04:23PM  Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy Investor's Business Daily
07:05AM  Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-11-18 08:13PM  How Bristol-Myers Squibb Company Fell $18.8 Billion in October Motley Fool
Nov-09-18 03:17PM  Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update Zacks
02:23PM  Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag Zacks
01:25PM  Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018 Investor's Business Daily
08:56AM  The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp Zacks
07:31AM  Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Zacks
07:00AM  Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb ACCESSWIRE
Nov-08-18 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
01:42PM  Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources Reuters
01:39PM  Stada, Angelini among final bidders for $1 bln Bristol-Myers' UPSA unit - sources Reuters
01:14PM  Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources Reuters
11:36AM  Edited Transcript of BMY earnings conference call or presentation 25-Oct-18 2:30pm GMT Thomson Reuters StreetEvents
11:13AM  Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise Zacks
11:07AM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3 Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM